EVERGREEN THERAPEUTICS - Key Persons
Job Titles:
- Associate Director
- Master of Biochemistry and Molecular
Master of Biochemistry and Molecular Biology, Anhui University. Worked for Pfizer China cardiovascular and anti-inflammatory and analgesic unit as SMICS; SMICS for the full product of Bo Ruilin Group.
Job Titles:
- Director of AI Bioinformatics / Director of AI Bioinformatics
Graduated from Beijing Normal University, received his Ph.D. in Biology from Uppsala University, and postdoctoral fellow at Kanarinska Institutet, Sweden; He was a former Director of the Bioinformatics Centre at the University of Melbourne, and is a scientist with many years of experience in bioinformatics engineering and genomics research.
Job Titles:
- Co - Founder, CEO / Co - Founder, CEO
He received his PhD in Biochemistry, University of Florida in the USA. He also did postdoctoral research at the National College of Medicine in the United States. Former FDA review officer, senior executives of many large and medium-sized international pharmaceutical companies, experts familiar with the entire process of FDA and global drug development, manufacturing, quality management, clinical design, drug product marketing application, and global post-marketing management of drug products. Dr. Du used to be a CMC reviewer of FDA, responsible for IND and BLA review of biological drugs. Subsequently, he worked at Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis, BMS, NPS and other multinational pharmaceutical companies. In the pharmaceutical industry more than 20 years of work, prevent new doctor for four biological medicine licenses approved by FDA, two biological drug approvals in the European Union and Canada, and countless IND in the United States, China, Europe, and other state approval, related to the size of the molecules, cells and genes, soluble tumor virus and medical devices and other various types of products. He has experience in managing medicines marketed in more than 30 countries. View More
Job Titles:
- Chief Medical Officer
- Member of the Business Team
- Co - Founder, CMO / Co - Founder, CMO
Dr. Charles Lee joined Evergreen Therapeutics as Chief Medical Officer
He graduated from Xi 'an Jiaotong University School of Medicine and received his Master's degree in hospital Administration and doctor of Public Health degree from the University of Alabama Birmingham, USA. He did three years of residency at the University of Chicago Medical Center and obtained the American Physician license and the American Clinical Pathology Specialist certification. He used to be a senior medical reviewer of THE US Food and Drug Administration (FDA), and was the first overseas Chinese to enter FDA's clinical review as a doctor. Dr. Charles Lee has extensive experience in phase I-IV global clinical trials in oncology, immunotherapy, anti-inflammatory, gastrointestinal diseases, and gynecological diseases. He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing overall solutions for global drug development, regulatory registration, clinical strategy and risk management.
Job Titles:
- Clinical Development Consultant of Anticancer and
- Leader of FDA
Dr. Houn is a former outstanding leader of FDA, having served as the Office Director of CDER, CBER, and CDRH for 15 years. She also served as executive in MNCs, and is a former professor at Johns Hopkins University and an oncologist. Dr. Houn is currently a clinical development consultant of anticancer and other drugs in Evergreen.
Job Titles:
- Senior Director of Public Affairs / Senior Director of Public Affairs
Graduated from Newcastle University Business School; and received a MSc in Project Management from the University of Manchester; with PRINCE2 certified for project management by UK government. He started his healthcare career at Omnicom Health Group AP and served as Executive Assistant; he provided market consulting services for several MNCs including MSD, Pfizer and Novartis. Prior to joining Evergreen, he was the Vice President of Continental Capital and has abundant experience in the market research and investment field of the pharmaceutical industry.
Job Titles:
- Clinical Development Consultant for Fundus Diseases
Director of the Department of Retinology at the Johns Hopkins University School of Medicine, Wilmer Institute of Ophthalmology; Doctor of Medicine from the University of Pennsylvania School of Medicine; Worked at Wells Eye Hospital in Philadelphia, Duke University Eye Center, and UCLA Children's Hospital; He has studied ophthalmic retinal, vitreous, and ophthalmic tumor diseases for many years, published hundreds of scientific research articles, and developed animal models of dry AMD.
Job Titles:
- Clinical Development Consultant in Basic Science and Respiratory Diseases
- Specialist, Former Chief of Internal Medicine at McGill University
Dr. Martin is a renowned respiratory specialist, former chief of internal medicine at McGill University, former director of the Respiratory Disease Institute, and a leading expert in asthma and COPD, especially in asthma pathophysiology research. Currently he serves as a consultant of Evergreen on basic science and clinical trials of respiratory diseases.
Graduated from the University of Miami with an MBA and a Master of Biostatistics. He has more than 15 years of experience in the pharmaceutical industry and more than 5 years of business development experience. He has worked in US-listed pharmaceutical companies and pharmaceutical consulting companies for many years, and has worked in AOB and Humphrey Pharmaceutical Consulting, serving as Deputy General Manager of Business Development and Assistant to the president. He is familiar with the daily operation of innovative pharmaceutical companies and has extensive experience in business cooperation, patent planning and technology transfer of pharmaceutical projects.
Job Titles:
- Business Development Director
Job Titles:
- Clinical Development Consultant of Immunology
PhD in Clinical Pharmacology, Diploma from Harvard Business School Executive Education. An outstanding physician and clinical pharmacologist with more than 35 years of experience in pharmaceutical industry and drug development led the R&D of 25 new drugs including epirubicine, imatinib. Expertise in a wide variety of therapeutic areas.
Job Titles:
- VP, Clinical Operation / VP, Clinical Operation
PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.
Job Titles:
- Chairman of Department of Gynecologic Oncology
- Clinical Development Consultant in Oncology
Dr. Moore is the Chair of Department of Gynecologic Oncology at the University of Rochester Medical Center. Former chair of the Department of Gynecologic Oncology at Brown University. He is an internationally recognized expert who uses biomarkers to detect ovarian cancer. Dr. Moore has a strong professional relationship with Evergreen and currently serves as the clinical development consultant in oncology.
Job Titles:
- Clinical Development Consultant of COVID - 19 Drugs
Dr. Malone is renowned infectious disease expert. He received M.D. degree in Northwestern University, was postdoctoral fellow at Harvard University. He has more than 20 years of experience in clinical development of new drugs and participated in the design and supervision of about 40 clinical trials from Phase I to Phase III. Currently he is serving as a consultant of Evergreen on novel Coronavirus treatment drug development.
Job Titles:
- Consultant for AI - Assisted Drug Development
Head of Structural Biology, Computer-Aided Drug Design, and Chemoinformatics at Sanofi, US ; Dr. Vaz has extensive experience in AI drug discovery in the fields of rare diseases, immunology, and neuroscience, providing computer-aided drug design for projects in these areas.
Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.
Master of Economics from Central University of Finance and Economics, MBA from Nanyang Technological University, Singapore. After that, She served as founding partner and general manager in many financial institutions including Pivot Capital and Jinhui Xingye Investment Management. Engaged in investment banking consulting business for 15 years, she has rich experience in the fields of corporate financing, M&A and listing financing. Ms. Yang has also made many achievements in the field of medicine, once served as the Deputy Secretary General of the China Pharmaceutical Industry Association and is currently the Vice President and Secretary General of the Gene Branch of the China Association of Traditional Chinese Medicine Information.
Job Titles:
- Senior Director of Pharmacology / Senior Director of Pharmacology
Bachelor of Pharmacy, Master of Pharmacology, Peking University Health Science Center; Doctor of Biomedical Science, Chinese University of Hong Kong. Postdoctoral fellow, School of Pharmacy, University of Washington, 2015-2018. Scientist, Clinical Pharmacology Division, FDA, 2018-2020. He has published more than 20 research papers in the fields of pharmacology, pharmacokinetics and drug interactions, and participated in editing and writing 2 academic papers. He has rich experience in pharmacological experiment design and drug mechanism research.
Job Titles:
- Member of the Management Team
- Founder, Chairman / Founder, Chairman
He graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.
Graduated from the Academy of Science of Leiden University in the Netherlands, he obtained a Ph.D. in Computational Medicinal Chemistry, and worked at Beijing Oriental Yamei Gene Technology Co., Ltd. as a Bioinformatics Engineer. His main research direction is artificial intelligence design of new drug molecules, and he has in-depth research in the fields of data mining, algorithms, protein engineering, and molecular simulation. View More